Several S1R agonists are FDA-approved (Ishikawa and Hashimoto, 2009), such as fluvoxamine (Nishimura et al., 2008) and donepezil (Maurice et al., 2006b) and they may be repurposed for the treatment of several neurodegenerative diseases. Here, TMBIM4 is linked to neurodegenerative disease.